Nadolol Pregnancy and Breastfeeding Warnings
Brand names: Corgard
Medically reviewed by Drugs.com. Last updated on Aug 12, 2024.
Nadolol Pregnancy Warnings
This drug should be used during pregnancy only if the benefit outweighs the risk to the fetus.
US FDA pregnancy category: Not Assigned
Risk summary: Inadequate data available on the use of this drug in pregnant women to inform a drug-related risk.
Animal studies have revealed evidence of embryotoxicity and fetotoxicity, but not teratogenicity. There are no controlled data in human pregnancy.
US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D, and X are being phased out.
Nadolol Breastfeeding Warnings
A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother.
Excreted into human milk: Yes
See also
References for pregnancy information
- (2002) "Product Information. Corgard (nadolol)." Bristol-Myers Squibb
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
- (2023) "Product Information. Corgard (nadolol)." US WorldMeds LLC
- (2024) "Product Information. Nadolol (nadolol)." BluePoint Laboratories
References for breastfeeding information
- (2002) "Product Information. Corgard (nadolol)." Bristol-Myers Squibb
- Cerner Multum, Inc. "UK Summary of Product Characteristics."
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.